Cytokines - Current status and perspectives in the treatment of skin tumors;Zytokine. Stand und perspektiven in der behandlung von hauttumoren

Hautarzt

Volumn 52, Issue 8, 2001, Pages 691-696

  Nashan, D ^a   Luger, T A ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cytokines; Lymphoma; Melanoma; Overview

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7;

B CELL LYMPHOMA; BASAL CELL CARCINOMA; GERMANY; HUMAN; MELANOMA; MERKEL CELL TUMOR; PUVA; REVIEW; SKIN LYMPHOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA;

EID: 0034889598     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050170082     Document Type: Review

References (96)

1. Comparison of the effects of intralesional interferon alfa-2a,2b and the combination of 2a and 2b in the treatment of basal cell carcinoma
2. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
3. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
4. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
5. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
6. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma
7. Targeted interleukin-2 therapy for melanoma by immunocytokines
8. Adjuvante therapie des primären malignen melanoms mit natürlichem humanem interferon beta
9. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)
10. New perspectives in experimental and clinical research for cutaneous T cell lymphomas
11. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma
12. Tumour cell expression of B7 costimulatory molecules and interleukin 12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity
13. Intralesional interferon therapy for basal cell carcinoma
14. Adjuvant therapy for cutaneous malignant melanoma
15. Regional and intralesonal treatment of invasive basal cell carcinoma with interferon alfa-2b
16. Extracorporal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma
17. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma
18. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma
19. Therapeutischer einsatz von interleukin-2 beim melanom
20. Treatment of Merkel cell tumour with interferon alpha-2b
21. Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy
22. Verminderte progressionsrate und induktion tumorspezi fischer immunantworten durch adjuvante immuntherapie bei stadium-IV-melanomen
23. Treatment of metastatic malignant melanom. Review paper
24. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene
25. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice
26. Treatment of basal cell carcinoma with intrament interferon
27. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. French cooperative group on melanoma
28. Peritumoral appliziertes IL-2 induziert tumorregression beim melanom
29. Role of the endogenous production of interleukin 12 in immunotherapy
30. Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma -draining lymph node cells impaired at a late tumor-bearing state
31. Two cases of Merkel cell carcinoma cured by intratumor injection of natural human tumor necrosis factor
32. Adjuvante interferon-alpha-therapie beim melanom
33. Current comments on the dermatological oncology working groups on high dose therapy with interferon alpha 2b
34. Adjuvante interferontherapie des melanoms
35. Effect of granulocyte-macrophage colony-stimulating factor treatment on phenotype, cytokine release and cytotoxicity of circulating blood monocytes and monocyte-derived macrophages
36. New aspects of immunotherapy of leptomeningeal metastasis
37. Therapeutic alternatives in cutaneous T-cell lymphoma
38. A chimeric Lym-1/interleukin2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake
39. Merkel cell carcinoma. A succesful treatment with tumor necrosis factor
40. Cutaneous malignant lymphomas
41. Randomized phase II trial of BCDT, cisplatin, dacarbazine and tamoxifen with or withour interferon alpha and interleukin 2 in patients with metastatic melanoma
42. Generation of a systemic antitumor response with regional intratumoral injections of interferon gamma retroviral vector
43. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
44. Sequential chemoimmunotherapy with cisplatin, interleukin-2,and interferon alfa-2a for metastatic melanoma
45. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogenic fibroblasts prolongs the survival of mice with melanoma
46. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2+ IFN-gamma
47. Chemo-/immuntherapie beim fortgeschrittenen malignen melanom: Carboplatin und DTIC oder cisplatin, DTIC, BCNU und tamoxifen und anschließende immuntherapie mit interleukin-2 und interferon-alpha2a
48. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
49. Sustained cytokine delivery for anticancer vaccination: Liposomes as alternative for gene-transfected tumor cells
50. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4
51. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and sezary syndrome
52. IL-12: A key cytokine in immune regulation
53. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice
54. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice
55. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
56. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy
57. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma
58. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha),interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study
59. 13-Cis-retinoic acid and interferon- alpha2a: Efffective combination therapy for advanced squamous cell carcinoma of the skin
60. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
61. 389IL-2 fusion toxin in mycosis fungoides
62. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic acitivity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
63. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
64. Application of interleukin 12 to antitumor cytokine and gene therapy
65. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study
66. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects
67. Multimodality management of merkel cell carcinoma
68. Therapie kutaner T-zell-lymphome mit PUVA versus interferon alpha plus PUVA. Erste ergebnisse des prospektiven randomisierten multi-zentrischen therapieoptimierungsprotokolls
69. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?
70. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
71. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma
72. Pathogenesis of cutaneous T cell lymphoma: Implications for the use of recombinant cytokines and photopheresis
73. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
74. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
75. Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma
76. Eastern cooperative group trial of interferon gamma in metastatic melanoma: An innovative study design
77. Cancer vaccines: The interleukin 2 dosage effect
78. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
79. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA
80. Sustained-release interleukin-12 microspheres in the treatment of cancer
81. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
82. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II
83. Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery
84. Response to hight dose cyclophosphamide with GM-CSF in Merkel cell tumor
85. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
86. Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon 26 cells in BALB/c mice
87. Guidelines for the managment of basal cell carcinoma
88. Trabecular carcinoma of the skin
89. Merkel cell carcinoma occurring in renal transplant patients
90. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A Southwest Oncology Group study
91. Treatment of neoplastic skin lesions with intralesional interferon
92. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII)
93. IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: A mechanism for its antitumor activity?
94. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo